ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update [Yahoo! Finance]
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Life Sciences Investor Forum Agenda Announced for November 14th
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs